Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Adjuvantno zdravljenje raka debelega črevesa
Authors:Ocvirk, Janja (Author)
Language:Slovenian
Tipology:1.08 - Published Scientific Conference Contribution
Organisation:Logo OI - Institute of Oncology
Abstract:Incidenca raka debelega črevesa še vedno narašča. Odkrit v zgodnjem stadiju je ozdravljiva bolezen že s samo kirurškim posegom. Pri bolnikih stadija I in večini stadija II je operacija dovolj ter ne potrebujejo dodatnega zdravljenja. Bolniki stadija III potrebujejo dodatno zdravljenje z adjuvantno kemoterapijo, saj ta zmanjša število ponovitev bolezni in s tem podaljša celotno preživetje ter vodi k večjemu številu ozdravljenih bolnikov. Glede na rezultate nedavnih raziskav pa tudi bolnikom stadija II glede na prisotnost rizičnih dejavnikov priporočamo zdravljenje z adjuvantno kemoterapijo.
Keywords:adjvantno zdravljenje, rak debelega črevesa, rak danke, rak prebavil
Year of publishing:2013
COBISS_ID:1554555 Link is opened in a new window
UDC:616.3-006-08
ISSN on article:1408-1741
OceCobissID:1553275 Link is opened in a new window
URN:URN:NBN:SI:doc-2HLK7W6A
Views:2473
Downloads:549
Files:.pdf PDF - Presentation file, download (301,75 KB)
 
Journal:Šola tumorjev prebavil, Ljubljana, 30. 11. 2012
Onkološki inštitut
 
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Rights:by Authors
:
  
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Adjuvant treatment of colon cancer
Abstract:The incidence of colon cancer is still increasing. If detected at an early stage, it is already curable by surgery alone. In patients with stage I disease and in the majority of patients with stage II disease, surgery is sufficient, and no additional treatment is required. However, stage III patients require additional treatment with adjuvant chemotherapy, as the latter reduces the number of disease recurrences, thus prolonging the overall survival and leading to a larger number of cured patients. Considering the results of the recent studies, stage II patients are also recommended to undergo adjuvant chemotherapy, depending on the presence of risk factors.

Archive

niGradiv

Back